[go: up one dir, main page]

NO20083333L - Fremgangsmater for forbedring av farmakokinetikken til HIV-integraseinhibitorer - Google Patents

Fremgangsmater for forbedring av farmakokinetikken til HIV-integraseinhibitorer

Info

Publication number
NO20083333L
NO20083333L NO20083333A NO20083333A NO20083333L NO 20083333 L NO20083333 L NO 20083333L NO 20083333 A NO20083333 A NO 20083333A NO 20083333 A NO20083333 A NO 20083333A NO 20083333 L NO20083333 L NO 20083333L
Authority
NO
Norway
Prior art keywords
hiv integrase
pharmacokinetics
improving
methods
integrase inhibitors
Prior art date
Application number
NO20083333A
Other languages
English (en)
Inventor
Brian P Kearney
Atsuyuki Kakee
Isao Kawaguchi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO20083333L publication Critical patent/NO20083333L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen tilveiebringer fremgangsmåter for forbedring av farmakokinetikken til en HIVintegraseinhiberende forbindelse ved administrering av mat og/eller ritonavir eller et farmasøytisk akseptabelt salt derav sammen med HIV-integraseinhibitoren.
NO20083333A 2005-12-30 2008-07-29 Fremgangsmater for forbedring av farmakokinetikken til HIV-integraseinhibitorer NO20083333L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75503905P 2005-12-30 2005-12-30
US75663106P 2006-01-06 2006-01-06
US76390106P 2006-02-01 2006-02-01
PCT/US2006/049668 WO2007079260A1 (en) 2005-12-30 2006-12-29 Methods for improving the pharmacokinetics of hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
NO20083333L true NO20083333L (no) 2008-09-29

Family

ID=38016698

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083333A NO20083333L (no) 2005-12-30 2008-07-29 Fremgangsmater for forbedring av farmakokinetikken til HIV-integraseinhibitorer

Country Status (16)

Country Link
US (1) US20070219243A1 (no)
EP (2) EP2308490A1 (no)
JP (1) JP4676536B2 (no)
KR (3) KR20160074018A (no)
CN (1) CN104069108A (no)
AP (1) AP2702A (no)
AU (1) AU2006332664B2 (no)
BR (1) BRPI0620865A2 (no)
CA (2) CA2847871C (no)
EA (2) EA018544B1 (no)
HR (1) HRP20080313A2 (no)
IL (1) IL192208A (no)
NO (1) NO20083333L (no)
NZ (1) NZ569576A (no)
SG (2) SG170795A1 (no)
WO (1) WO2007079260A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AP2986A (en) 2007-02-23 2014-09-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
NZ582086A (en) * 2007-06-29 2012-07-27 Gilead Sciences Inc Therapeutic compositions and the use thereof
UA103881C2 (ru) * 2007-06-29 2013-12-10 Гилиад Сайенсиз, Инк. Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека
GB2470494B (en) * 2008-01-17 2012-08-08 Univ Holy Ghost Duquesne Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS
SI2531027T1 (sl) * 2010-01-27 2015-08-31 Viiv Healthcare Company Terapevtska kombinacija, ki obsega dolutegravir, abakavir in lamivudin
WO2013109354A2 (en) * 2011-12-07 2013-07-25 Texas Southern University Etravirine formulations and uses thereof
CN116640140A (zh) 2012-12-21 2023-08-25 吉利德科学公司 多环-氨基甲酰基吡啶酮化合物及其药物用途
RS56540B1 (sr) 2013-07-12 2018-02-28 Gilead Sciences Inc Policiklična karbamoilpiridonska jedinjenja i njihova upotreba za lečenje hiv infekcija
NO2865735T3 (no) 2013-07-12 2018-07-21
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (no) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
IL296496B2 (en) 2014-12-26 2024-10-01 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
AU2016354007C9 (en) 2015-11-09 2020-10-01 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
CA2585898C (en) 1992-12-29 2009-10-20 Abbott Laboratories Use of (2s,3s,5s)-5-(n-(n-((n-methyl-n-((2-isopropyl-4-thaizolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(n-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane in combination with another protease inhibitor for treating hiv infection
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
NZ515016A (en) * 1999-06-04 2004-02-27 Abbott Lab HIV protease inhibitor composition
US6541515B2 (en) 2000-08-09 2003-04-01 Merck & Co., Inc. HIV integrase inhibitors
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
WO2004035577A2 (en) 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
DE60329318D1 (de) * 2002-11-20 2009-10-29 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
EP1590349A1 (en) * 2003-01-27 2005-11-02 Pfizer Inc. Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
EP1622615A4 (en) * 2003-05-13 2009-02-18 Smithkline Beecham Corp INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP2229945A1 (en) * 2004-05-21 2010-09-22 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
CA2610167A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Administration of hcv protease inhibitors in combination with food to improve bioavailability
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2007296555B2 (en) * 2006-09-12 2012-07-12 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
UA103881C2 (ru) * 2007-06-29 2013-12-10 Гилиад Сайенсиз, Инк. Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека
NZ582086A (en) * 2007-06-29 2012-07-27 Gilead Sciences Inc Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa

Also Published As

Publication number Publication date
EP2308490A1 (en) 2011-04-13
EA201201496A1 (ru) 2013-07-30
BRPI0620865A2 (pt) 2011-11-29
AU2006332664B2 (en) 2013-03-14
AU2006332664A1 (en) 2007-07-12
CA2847871A1 (en) 2007-07-12
CA2635468C (en) 2016-08-09
SG170796A1 (en) 2011-05-30
KR101524165B1 (ko) 2015-06-01
WO2007079260A1 (en) 2007-07-12
CA2635468A1 (en) 2007-07-12
WO2007079260A9 (en) 2007-08-30
EP1976517A1 (en) 2008-10-08
JP4676536B2 (ja) 2011-04-27
KR20160074018A (ko) 2016-06-27
KR20080081358A (ko) 2008-09-09
JP2009525265A (ja) 2009-07-09
AP2008004522A0 (en) 2008-06-30
KR20140082858A (ko) 2014-07-02
SG170795A1 (en) 2011-05-30
HRP20080313A2 (en) 2008-11-30
EA018544B1 (ru) 2013-08-30
US20070219243A1 (en) 2007-09-20
AP2702A (en) 2013-07-23
CN104069108A (zh) 2014-10-01
IL192208A0 (en) 2009-02-11
EA200801619A1 (ru) 2008-10-30
NZ569576A (en) 2011-09-30
CA2847871C (en) 2016-07-26
IL192208A (en) 2013-10-31

Similar Documents

Publication Publication Date Title
NO20083333L (no) Fremgangsmater for forbedring av farmakokinetikken til HIV-integraseinhibitorer
UA89220C2 (ru) Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
BRPI1011838A2 (pt) composto de carboxamida heterocíclica de diamino
WO2017109488A8 (en) Cyanopyrrolidine derivatives as inhibitors for dubs
NO20063958L (no) HIV integrase inhibitorer
HUS1400039I1 (hu) HIV Integráz inhibitor hatással rendelkezõ policiklusos karbamoilpiridon-származékok
ATE518844T1 (de) Kaliumsalz eines hiv-integrase-inhibitors
NZ593012A (en) Heterocyclic aspartyl protease inhibitors and their combination with cholinesterase inhibitors or muscarinic antagonists
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
CA2983481A1 (en) Janus kinase inhibitor
NO20070751L (no) Inhibitorer av HCV-replifikasjon
WO2006130686A3 (en) Hcv protease inhibitors in combination with food
NO20064555L (no) HIV-integraseinhibitorer.
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
ATE461202T1 (de) Hiv-integrasehemmer
WO2003065987A3 (en) Granzyme b inhibitors
NO20073370L (no) Kombinasjoner som innbefatter epotiloner og proteintyrosinkinaseinhibitorer og farmasoytiske anvendelser derav
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
EA200801199A1 (ru) Ингибиторы киназы
WO2008048121A3 (en) Macrocyclic cysteine protease inhibitors and compositions thereof
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
WO2007019098A3 (en) Hiv integrase inhibitors
WO2009106599A3 (en) Substituted piperidines as therapeutic compounds
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.
WO2009148600A3 (en) Deuterated lysine-based compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application